Stuart Merl | Biological Therapy/Immunotherapy Chemotherapy Gene Therapy Pain Management Targeted Therapy

Stuart Merl, MD

Medical Oncologist

Conditions Treated

Laryngeal Cancer Lung Cancer Ovarian Cancer Pericardial Mesothelioma Peritoneal Mesothelioma Pleural Mesothelioma Testicular Mesothelioma

specialties & services

Biological Therapy/Immunotherapy Chemotherapy Gene Therapy Pain Management Targeted Therapy

Hospitals & Clinics

Bio & Insurance Information

Insurance Accepted

Aetna Choice POS II Aetna HMO First Health PPO

Education & Training

Warren Alpert Medical School of Brown University

Medical School

Medical College of Pennsylvania and Hospital

Residency

SUNY Upstate Med University

Fellowship

Board Certifications

American Board of Internal Medicine

American Board of Internal Medicine - Hematology

American Board of Internal Medicine - Oncology

Medical License

OH State Medical License Active through 2018

Hospitals & Clinics

Publications

Dr. Stuart Merl has contributed to 1 publications.

A phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group study (S0331).

Samlowski, W.E., Moon, J., Tuthill, R.J., Heinrich, M.C., Balzer-Haas, N.S., Merl, S.A., DeConti, R.C., Thompson, J.A., Witter, M.T., Flaherty, L.E., Sondak, V.K.; Am J Clin Oncol. 2010 Oct.